SUN PHARMA - Urgent requirement for Production, QA, Warehouse, Process Engineer & IT Executive.
About Sun Pharma:-
Sun Pharma Laboratories Limited ("SPLL" or "Company") is a pharmaceutical company registered with Mumbai, Maharashtra. The company prepares and markets pharmaceutical products in India. They were included on January 17, 1997.
The domestic formulation of SPIL has been transferred to the company from March 31, 2012, under the scheme of Undertaking Sun Pharmaceutical Industries Limited and the company. Company shares are not listed on any stock exchange.
SPLL is engaged in the business of promoting and promoting generic pharmaceutical products and has 5.6% market price as per the AIODD AVAVS-October 2015. The company's four plants are located in Sikkim and Jammu.
It is a strong step in the therapeutic departments of neurology and psychotherapy, central nervous system, cardiology, gastroenterology, diabetes, gynecology etc. The company is the leader of the Indian market in the long term segment, which earns more than 60% according to AIOCD. AWACS-October 2015.
It technically provides a complete therapy basket with expertise in complex products. Of the top 300 pharmaceutical brands in the country, SPLL has 19 brands. India has a strong area of over 300,000 doctors who advertise products to 150,000 doctors across India.
The performance of Field Force is well-trained to the overpowering vendors and the highest productivity of the Indian pharma companies is achieved. Over the years, the company has developed an average industry. According to the SMSRC report, according to February 2015, the doctor's no. It is number 1.
We were pioneers in Indian Pharmaceutical companies to see the huge value of an investment in R & D. Our initial investment in R & D three decades ago, enables us to make our main difference in technology and to develop a strong product basket for different markets around the world. Formulations, process chemistry, and our focus on enhancing our excellent ability in the development of generic and technically complex products by the focusing teams in analytical development. You have the ability to distribute quality products in a set of timelines established at a lower cost and without compromise on quality.
There are about 2000 research scientists working on multiple R & D centers capable of state-of-the-art technology for research. It is difficult to create our scientists for generic development, technology-intensive products, active pharmaceutical ingredients (APIs), new drug delivery systems (NDS) and new chemical companies (NCE).
Our ability develops the development of nuclear products, in addition to developing liposomal products, inhalers, localized injections, nasal spray, and controlled release dosage form.
Our information in Pharmaceutical Research allows for a quick ramp-up of various range of instant and new delivery systems in oral, parental, topical and inhalation dosage forms. Our formulation expert is in the area of taste masking, spray-drying, drug leveling, nano-milling, lifefillation and other pharmaceutical unit operations, which enables us to meet different formulation design requirements and concepts. The ability to develop a complex API, using sophisticated technology to create a difficult-to-computer, is a major component of our research.
To develop new scientific concepts and ideas, our scientists work closely with our professional development team to absorb the market needs of the therapeutic sector and the colleagues. According to research, we invest 7-8 percent of your income every year. In the same way, we constantly monitor the research potential of focusing on developing new technologies. Indian general companies have the highest R & D productivity.
For many years we have developed experts in the field of pharmacokinetic and bioequalvans to facilitate generic or branded generic medicines for international markets. Our 408-bed clinical pharmacology unit works on biological / biogevelopment studies in GCP compliance with expert staffers. A phase is a full-site facility for the first clinical studies. Our CPU has been inspected by US FDA, ANTISIA, MHRA and DCGI.
Our research strategies and implementation have been done by a good intellectual property team that has experience and experience of chemistry, analytical techniques, dosage form and global patent law. In the past 10 years, we have been consistently successful in challenging patents with first-to-file specifications under the Hatch-Waxman Act in America and have helped bring such a cheap, high-quality version of such products. Otherwise market as quickly as possible.
Our ability to research does not only give us rich dividends in terms of business but also gives us a tremendous reputation for quality and ability. The most amazing evidence came when the US FDA permitted us to import liposomal doxorbicin, which was not allowed. In US and Europe, we are among the few general companies in products like Azellstein Nasal Spray and Sumatripten Autoinjictor.
Our F & D centers have been inspected and approved by the International Regulatory Authority including the US FDA and European authorities.
